Cargando…

Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds

INTRODUCTION: The aim of this study was to explore changes in glomerular filtration (GFR) and renal tubular function in critically ill patients at risk of augmented renal clearance (ARC), using exogenous marker compounds. METHODS: This prospective, observational pharmacokinetic (PK) study was perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Udy, Andrew A, Jarrett, Paul, Stuart, Janine, Lassig-Smith, Melissa, Starr, Therese, Dunlop, Rachel, Wallis, Steven C, Roberts, Jason A, Lipman, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271452/
https://www.ncbi.nlm.nih.gov/pubmed/25432141
http://dx.doi.org/10.1186/s13054-014-0657-z
_version_ 1782349607367344128
author Udy, Andrew A
Jarrett, Paul
Stuart, Janine
Lassig-Smith, Melissa
Starr, Therese
Dunlop, Rachel
Wallis, Steven C
Roberts, Jason A
Lipman, Jeffrey
author_facet Udy, Andrew A
Jarrett, Paul
Stuart, Janine
Lassig-Smith, Melissa
Starr, Therese
Dunlop, Rachel
Wallis, Steven C
Roberts, Jason A
Lipman, Jeffrey
author_sort Udy, Andrew A
collection PubMed
description INTRODUCTION: The aim of this study was to explore changes in glomerular filtration (GFR) and renal tubular function in critically ill patients at risk of augmented renal clearance (ARC), using exogenous marker compounds. METHODS: This prospective, observational pharmacokinetic (PK) study was performed in a university-affiliated, tertiary-level, adult intensive care unit (ICU). Patients aged less than or equal to 60 years, manifesting a systemic inflammatory response, with an expected ICU length of stay more than 24 hours, no evidence of acute renal impairment (plasma creatinine concentration <120 μmol/L) and no history of chronic kidney disease or renal replacement therapy were eligible for inclusion. The following study markers were administered concurrently: sinistrin 2,500 mg (Inutest; Laevosan, Linz, Austria), p-aminohippuric acid (PAH) 440 mg (4% p-aminohippuric acid sodium salt; CFM Oskar Tropitzsch, Marktredwitz, Germany), rac-pindolol 5 or 15 mg (Barbloc; Alphapharm, Millers Point, NSW, Australia) and fluconazole 100 mg (Diflucan; Pfizer Australia Pty Ltd, West Ryde, NSW, Australia). Plasma concentrations were then measured at 5, 10, 15, 30, 60 and 120 minutes and 4, 6, 12 and 24 hours post-administration. Non-compartmental PK analysis was used to quantify GFR, tubular secretion and tubular reabsorption. RESULTS: Twenty patients were included in the study. Marker administration was well tolerated, with no adverse events reported. Sinistrin clearance as a marker of GFR was significantly elevated (mean, 180 (95% confidence interval (CI), 141 to 219) ml/min) and correlated well with creatinine clearance (r =0.70, P <0.01). Net tubular secretion of PAH, a marker of tubular anion secretion, was also elevated (mean, 428 (95% CI, 306 to 550) ml/min), as was net tubular reabsorption of fluconazole (mean, 135 (95% CI, 100 to 169) ml/min). Net tubular secretion of (S)- and (R)-pinodolol, a marker of tubular cation secretion, was impaired. CONCLUSIONS: In critically ill patients at risk of ARC, significant alterations in glomerular filtration, renal tubular secretion and tubular reabsorption are apparent. This has implications for accurate dosing of renally eliminated drugs.
format Online
Article
Text
id pubmed-4271452
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42714522014-12-20 Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds Udy, Andrew A Jarrett, Paul Stuart, Janine Lassig-Smith, Melissa Starr, Therese Dunlop, Rachel Wallis, Steven C Roberts, Jason A Lipman, Jeffrey Crit Care Research INTRODUCTION: The aim of this study was to explore changes in glomerular filtration (GFR) and renal tubular function in critically ill patients at risk of augmented renal clearance (ARC), using exogenous marker compounds. METHODS: This prospective, observational pharmacokinetic (PK) study was performed in a university-affiliated, tertiary-level, adult intensive care unit (ICU). Patients aged less than or equal to 60 years, manifesting a systemic inflammatory response, with an expected ICU length of stay more than 24 hours, no evidence of acute renal impairment (plasma creatinine concentration <120 μmol/L) and no history of chronic kidney disease or renal replacement therapy were eligible for inclusion. The following study markers were administered concurrently: sinistrin 2,500 mg (Inutest; Laevosan, Linz, Austria), p-aminohippuric acid (PAH) 440 mg (4% p-aminohippuric acid sodium salt; CFM Oskar Tropitzsch, Marktredwitz, Germany), rac-pindolol 5 or 15 mg (Barbloc; Alphapharm, Millers Point, NSW, Australia) and fluconazole 100 mg (Diflucan; Pfizer Australia Pty Ltd, West Ryde, NSW, Australia). Plasma concentrations were then measured at 5, 10, 15, 30, 60 and 120 minutes and 4, 6, 12 and 24 hours post-administration. Non-compartmental PK analysis was used to quantify GFR, tubular secretion and tubular reabsorption. RESULTS: Twenty patients were included in the study. Marker administration was well tolerated, with no adverse events reported. Sinistrin clearance as a marker of GFR was significantly elevated (mean, 180 (95% confidence interval (CI), 141 to 219) ml/min) and correlated well with creatinine clearance (r =0.70, P <0.01). Net tubular secretion of PAH, a marker of tubular anion secretion, was also elevated (mean, 428 (95% CI, 306 to 550) ml/min), as was net tubular reabsorption of fluconazole (mean, 135 (95% CI, 100 to 169) ml/min). Net tubular secretion of (S)- and (R)-pinodolol, a marker of tubular cation secretion, was impaired. CONCLUSIONS: In critically ill patients at risk of ARC, significant alterations in glomerular filtration, renal tubular secretion and tubular reabsorption are apparent. This has implications for accurate dosing of renally eliminated drugs. BioMed Central 2014-11-29 2014 /pmc/articles/PMC4271452/ /pubmed/25432141 http://dx.doi.org/10.1186/s13054-014-0657-z Text en © Udy et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Udy, Andrew A
Jarrett, Paul
Stuart, Janine
Lassig-Smith, Melissa
Starr, Therese
Dunlop, Rachel
Wallis, Steven C
Roberts, Jason A
Lipman, Jeffrey
Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
title Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
title_full Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
title_fullStr Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
title_full_unstemmed Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
title_short Determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
title_sort determining the mechanisms underlying augmented renal drug clearance in the critically ill: use of exogenous marker compounds
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271452/
https://www.ncbi.nlm.nih.gov/pubmed/25432141
http://dx.doi.org/10.1186/s13054-014-0657-z
work_keys_str_mv AT udyandrewa determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT jarrettpaul determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT stuartjanine determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT lassigsmithmelissa determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT starrtherese determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT dunloprachel determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT wallisstevenc determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT robertsjasona determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds
AT lipmanjeffrey determiningthemechanismsunderlyingaugmentedrenaldrugclearanceinthecriticallyilluseofexogenousmarkercompounds